An interventional study of Standard fractioned dose and Reduced fractioned dose in Heel Spur Syndrome, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 1 site in Poland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Heel Spur Syndrome (HSS), is a pathology characterized by chronic inflammation and degenerative changes that affect approximately 10% of adults. Although many patients respond to conservative care, about 30% experience persistent pain. Low-dose radiation therapy (LDRT) is a well-established European method with proven anti-inflammatory and immunomodulatory effects. The ORHEELS trial aims to assess whether a Polish standard dose of 6 Gy in 6 daily fractions (fx)(5 times/week) is not inferior to the treatment with total dose of 3 Gy / fx 0,5 Gy /fractionated twice weekly. The study is designed to assess the impact of intensity of treatment (daily (5 times / week) versus twice weekly fractionation) on clinical outcomes.
The aim of this study is to optimize the fractionation schedules for radiotherapy in the treatment of HSS, through a prospective randomized non-inferiority clinical trial conducted at Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.
Purpose/Objective:
224 studies on the registry are indexed under Fasciitis, Plantar; 59 are open to participants now.
This study's planned enrollment of 366 is above the median of 56 across 194 interventional studies indexed under Fasciitis, Plantar.
Browse Fasciitis, Plantar studies →Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Polish Standard Dose
Radiation: Standard fractioned dose
Arm B (Reduced Dose)
Radiation: Reduced fractioned dose
(Reduced Dose \& Intensity)
Radiation: Reduced fractioned dose & Intensity
Total dose of 6 Gy (6 fractions of 1.0 Gy) administered 5 times per week
Total dose of 3 Gy (6 fractions of 0.5 Gy) administered 5 times a week.
Total dose of 3 Gy (6 fractions of 0.5 Gy) administered 2 times per week
Non-inferiority of reduced fraction dose radiotherapy of heel spur
The primary endpoint will be evaluated as the difference in treatment success rates between arms A and C and between arms B and C. Success of treatment will be defined as a ≥50% reduction in pain intensity measured using the VAS scale and assessed 3 months after the end of treatment using the Pannewitz-modified pain scale relative to the baseline. Analyses for the two equivalent non-inferiority comparisons (A vs. C and B vs. C) will be performed one-sided at a significance level of α = 0.0125 (after applying the Bonferroni correction), corresponding to 97.5% two-sided confidence intervals, assuming a success rate of 65% for all three treatment regimens and an acceptable non-inferiority margin of δ=0.2, expressed as a risk difference
Time frame: 3 months after treatment
Assessment of effectiveness in pain relief
Pain relief will be evaluated using: The Visual Analogue Scale (VAS) and The modified von Pannewitz pain scale.
Time frame: 3, 6, 12 and 24 months after treatment
Assessment of functional and gait improvement
Improvement will be measured using the Rowe Score scale.
Time frame: Before and 3, 6 and 12 months after treatment
Reirradiation rate
A comparison of the number of patients requiring reirradiation defined as the proportion of patients requiring a second course of radiotherapy within 12 months of initial treatment
Time frame: Up to 12 months after treatment
Assessment of treatment safety and tolerability
The skin toxicity evaluated according to the version 5 of the Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: Throughout the observation period
Patients' reported Quality of Life
Evaluation of the SF-36 questionnaires
Time frame: Before and 6, 12 months after the treatment
Evaluation of inflammatory markers
Evaluation of systemic inflammation (morphology, CRP, IL-6, fibrinogen, and TNF-α)
Time frame: Before treatment and 1 month after treatment
Assessment of treatment effectiveness
The assessment will be conducted in accordance with the definitions provided, depending on the size of the irradiated area and the duration of pain symptoms (less than or more than 6 months)
Time frame: 3, 6 and 12, 24 months after treatment
Started Mar 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.
Of 104 non-industry interventional studies with no phase under Fasciitis, Plantar, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's planned 47 months is above that.
Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 6 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maria Sklodowska-Curie National Research Institute of Oncology